Business Wire

TERRA-FIRMA-ENERGY

Share
Terra Firma Energy Limited Secure 120MW of Contracts From Record Breaking T-4 Capacity Market Auction

Terra Firma Energy have successfully secured 120MW of contracts in the record-breaking T-4 Capacity Market auction. After two bidding rounds the auction cleared at £65/kW/Year breaking last year’s record of £63/kW/Year. This outstanding result will see our contracted assets receive over £7.3M per year to be on standby to provide critical support to National Grid when required.

UK Capacity Market

The UK Capacity Market ensures electricity supply meets demand, especially during peak times, by incentivising generation investment and maintaining grid stability. Auction results determine prices paid to generators for ensuring electricity availability. The T-4 auction secures capacity for delivery in four years via long-term 15-year agreements, while T-1 auctions procure capacity just before delivery via 12-month agreements. On February 27, 2024, the T-4 auction cleared at £65/kW/year for delivery in Oct-2027/Sep-28.

William Davies, Managing Director of Terra Firma Energy said “I am thrilled to announce that our team has successfully secured 120MW of contracts in the latest T-4 Capacity Market auction. The record-breaking clearing price of the auction highlights the increasing importance of ensuring we create our generation development strategy with energy security as a core component. We are excited to be playing a key role in providing communities up and down the country with the energy security they need for the future.”

For more news from Terra Firma Energy please click here

Notes to Editors

About Terra Firma Energy Limited

Terra Firma Energy Limited are a privately owned U.K. based company operating in the development of renewable & sustainable energy projects. We design, develop & construct carefully sourced projects with the emphasis on making them a cleaner & more respectful source of energy production for future generations.

Website - Home - Terrafirma Energy
LinkedIn - https://www.linkedin.com/company/terra-firma-energy-limited/
you tube - https://youtube.com/@terrafirmaenergy?si=QXIeYkWajprAowg6
Facebook - https://www.facebook.com/profile.php?id=100090781489759
Instagram - https://www.instagram.com/terrafirmaenergyuk/
X - https://x.com/tfenergyuk?s=21&t=-U9hoHD9f4OzkyQSpY301A

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228312206/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press release

Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too f

Cinemo Launches Cinemo ICO™, Accelerating the AI-Driven Intelligent Cockpit19.12.2025 11:00:00 CET | Press release

The future of in-car intelligence, delivered today for hyper-personalized, safer, smarter, and more exceptional journeys Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products announces today the launch of its next-generation, AI-powered cockpit solutions - Cinemo ICO™. By bringing agentic AI, Cinemo unlocks a truly intelligent cockpit - connecting vehicles, drivers, passengers, and their digital ecosystems into one seamless, personal and context-aware flow. The first product launched within the Cinemo ICO™ portfolio is Cinemo ICO™ MediaMind, enabling advanced intelligent media discovery. It combines the latest agentic AI technology with Cinemo’s core expertise of providing automotive-grade media management, helping users effortlessly discover the right content for every ride - perfectly matched to their taste, context, and environment. With Cinemo ICO™ MediaMind, the digital media experience evolves: using cutting-edge large la

Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 08:00:00 CET | Press release

Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def

S3NS Announces SecNumCloud Qualification for PREMI3NS, its Trusted Cloud Offering19.12.2025 07:00:00 CET | Press release

PREMI3NS, S3NS’ (pronounced “sense”) trusted cloud offering, has now received ANSSI’s SecNumCloud qualification, meeting the most stringent protection requirements against extraterritorial laws in France and Europe The fruition of the partnership between Thales and Google Cloud enables organizations from the private and public sectors to innovate and transform with one of the broadest ranges of managed services in a trusted cloud environment Early adopters of S3NS include companies from the insurance, manufacturing, healthcare and finance industries S3NS, a subsidiary of Thales in partnership with Google Cloud, today announced that PREMI3NS, its "Trusted Cloud" (Cloud de confiance) offering, has received the SecNumCloud 3.2 qualification delivered by the French National Agency for the Security of Information Systems (ANSSI). Meeting SecNumCloud 3.2’s protection and resilience requirements, which are known as the most demanding ones in France and Europe, it offers immunity from non-Euro

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye